Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13
暂无分享,去创建一个
H. Zhou | D. Zhong | Y. Wang | H Zhou | D Si | Y Guo | Y Wang | P J Fawcett | D Zhong | Hui Zhou | P. J. Fawcett | D. Si | Y. Guo | H. Zhou | Dayong Si
[1] J. Goldstein,et al. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. , 2001, Pharmacogenetics.
[2] Jose Cosme,et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.
[3] R. Kim,et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. , 2001, Molecular pharmacology.
[4] H. Jinno,et al. Functional characterization of three human cytochrome P450 2E1 variants with amino acid substitutions , 2003, Xenobiotica; the fate of foreign compounds in biological systems.
[5] R. Kim,et al. CYP2C9 allelic variants: ethnic distribution and functional significance. , 2002, Advanced drug delivery reviews.
[6] J. Miners,et al. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. , 1993, The Biochemical journal.
[7] A. Gaedigk,et al. Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[8] H. Jinno,et al. Functional characterization of cytochrome P450 2B6 allelic variants. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[9] Eric F. Johnson,et al. The Structure of Human Cytochrome P450 2C9 Complexed with Flurbiprofen at 2.0-Å Resolution* , 2004, Journal of Biological Chemistry.
[10] D. Zhong,et al. Identification of a novel variant CYP2C9 allele in Chinese. , 2004, Pharmacogenetics.
[11] Jürgen Brockmöller,et al. Clinical Consequences of Cytochrome P450 2C9 Polymorphisms , 2005, Clinical pharmacology and therapeutics.
[12] M. Ingelman-Sundberg,et al. Genetic polymorphism of human CYP2E1: characterization of two variant alleles. , 1997, Molecular pharmacology.
[13] Slobodan Petar Rendic,et al. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.
[14] Xiaoyan Chen,et al. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. , 2005, British journal of clinical pharmacology.
[15] J. Goldstein,et al. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. , 2002, Pharmacogenetics.
[16] C R Lee,et al. CYP2C9 genotype as a predictor of drug disposition in humans. , 2004, Methods and findings in experimental and clinical pharmacology.
[17] S. Higuchi,et al. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis. , 2000, Therapeutic drug monitoring.
[18] Kaoru Kobayashi,et al. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. , 2000, Pharmacogenetics.
[19] O. Gotoh,et al. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. , 1992, The Journal of biological chemistry.